Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phoenix Sign Analysis: Lidocaine vs Papaverine in CPN Entrapment
NCT06919289Completed
- Sponsor
- US Neuropathy Centers
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of papaverine in Common peroneal nerve entrapment (CPNE) (2 arms), sponsored by US Neuropathy Centers. Primary endpoint: Manual Motor Strength Testing of Anterior Compartment at 1 day. Started Mar 2024; status: completed.
02
Drugs
papaverine
03
Conditions
Common peroneal nerve entrapment (CPNE)
Beyond the preview
Go deeper on NCT06919289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919289.